Skip to content
2000
Volume 16, Issue 1
  • ISSN: 1566-5232
  • E-ISSN: 1875-5631

Abstract

Advanced cardiac failure is a progressive intractable disease and is the main cause of mortality and morbidity worldwide. Since this pathology is represented by a definite decrease in cardiomyocyte number, supplementation of functional cardiomyocytes into the heart would hypothetically be an ideal therapeutic option. Recently, unlimited in vitro production of human functional cardiomyocytes was established by using induced pluripotent stem cell (iPSC) technology, which avoids the use of human embryos. A number of basic studies including ours have shown that transplantation of iPSCderived cardiomyocytes (iPSC-CMs) into the damaged heart leads to recovery of cardiac function, thereby establishing “proof-of-concept” of this iPSC-transplantation therapy. However, considering clinical application of this therapy, its feasibility, safety, and therapeutic efficacy need to be further investigated in the pre-clinical stage. This review summarizes up-to-date important topics related to safety and efficacy of iPSC-CMs transplantation therapy for cardiac disease and discusses the prospects for this treatment in clinical studies.

Loading

Article metrics loading...

/content/journals/cgt/10.2174/1566523216666160119094143
2016-02-01
2025-06-29
Loading full text...

Full text loading...

/content/journals/cgt/10.2174/1566523216666160119094143
Loading

  • Article Type:
    Research Article
Keyword(s): Cardiomyocytes; Cardiomyoplasty; Heart failure; Immunogenicity; iPSC; Transplantation
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test